Abstract 2020 archivos - Página 5 de 9

Rev Esp Quimioter 2020; 33(4): 274-277

Impact of Spanish Public Health Measures on Emergency Visits and COVID- 19 diagnosed cases during the pandemic in Madrid

FRANCISCO JAVIER MARTÍN-SÁNCHEZ, ADRIÁN VALLS CARBÓ, AMANDA LÓPEZ PICADO, CARMEN MARTÍNEZ-VALERO, JUANDE D. MIRANDA, JOSÉ MARÍA LEAL POZULEO, JUAN GONZÁLEZ DEL CASTILLO

Published: 10 June 2020

http://www.doi.org/10.37201/req/053.2020

Introduction. Changes in Public Health recommendations may have changed the number of emergency visits and COVID-19 diagnosed cases in an Emergency Department in Madrid.
Material and methods. This retrospective case series study included all consecutive patients in a tertiary and urban ED in Madrid from 1st to 31st March. The sample was divided: NonCOVID-19, Non-investigated COVID-19, Possible COVID-19, Probable COVID-19, Confirmed COVID-19. Differences between public health periods were tested by ANOVA for each cohort, and by ANCOVA including the number of PCR tests (%) as covariate.
Results. A total of 7,163 (4,071 Non-COVID-19, 563 Non-investigated COVID-19, 870 Possible, 648 Probable and 1,011 Confirmed COVID-19) cases were included. Public Health measurements applied during each period showed a clear effect on the case proportion for the five cohorts.
Conclusion. The variability of case definitions and diagnostic test criteria may have impact on the number of emergency visits and COVID-19 diagnosed cases in Emergency Department.

Rev Esp Quimioter 2020; 33(4): 274-277 [Full-text PDF]

10 junio, 2020/por Luis Alou

Rev Esp Quimioter 2020; 33(4): 285-288

Enfermedad pélvica inflamatoria por Streptococcus constellatus. Experiencia clínica y revisión de la literatura

(Pelvic inflammatory disease by Streptococcus constellatus. Clinical experience and a review)

JOSÉ CARLOS MORA-PALMA, VICENTE GUILLOT-SUAY, MARÍA DEL MAR SÁNCHEZ GILA, JOSÉ GUTIÉRREZ-FERNÁNDEZ

Published: 9 June 2020

http://www.doi.org/10.37201/req/020.2020

LETTER TO THE EDITOR

Rev Esp Quimioter 2020; 33(4): 285-288 [Texto completo PDF]

9 junio, 2020/por Luis Alou

Abstract, Abstract 2020

Rev Esp Quimioter 2020; 33(4): 226-239

High-dose trivalent influenza vaccine. Efficacy and effectiveness

ÁNGEL GIL DE MIGUEL, ESTHER REDONDO MARGUELLO, JAVIER DÍEZ DOMINGO, RAÚL ORTIZ DE LEJARAZU, FEDERICO MARTINÓN TORRES

Published: 9 June 2020

http://www.doi.org/10.37201/req/043.2020

Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trivalent influenza vaccine (IIV3-HD), containing four times more antigen than the standard-dose vaccine, was approved in the United States for the immunization of people aged 65 years and over. Numerous clinical trials, carried out at different seasons and using different methodologies, have shown that the IIV3-HD vaccine is, as well as safe, more immunogenic and more effective than the standard-dose vaccine in preventing influenza virus infection and its complications in older people. This paper reviews the available evidence on the efficacy and effectiveness of the IIV3-HD influenza vaccine in the elderly, with information from randomized clinical trials, as well as observational studies of real-world clinical practice and in systematic reviews/meta-analyses.

Rev Esp Quimioter 2020; 33(4): 226-239 [Texto completo PDF]

9 junio, 2020/por Luis Alou

Abstract, Abstract 2020

Rev Esp Quimioter 2020; 33(4): 240-248

Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence

FRANCISCO LEDESMA, MARÍA BUTI, RAQUEL DOMÍNGUEZ-HERNÁNDEZ, MIGUEL ÁNGEL CASADO, RAFAEL ESTEBAN

Published: 8 June 2020

http://www.doi.org/10.37201/req/030.2020

Background. Efficient strategies are needed in order to achieve the objective of the WHO of eradicating Hepatitis C virus (HCV). Hepatitis C infection can be eliminated by a combination of direct acting antiviral (DAA). The problem is that many individuals remain undiagnosed. The objective is to conduct a systematic review of the evidence on economic evaluations that analyze the screening of HCV followed by treatment with DAAs.
Methods. Eleven databases were performed in a 2015-2018-systematic review. Inclusion criteria were economic evaluations that included incremental cost-effectiveness ratio (ICER) in terms of cost per life year gained or quality-adjusted life year.
Results. A total of 843 references were screened. Sixteen papers/posters meet the inclusion criteria. Ten of them included a general population screening. Other populations included were baby-boomer, people who inject drugs, prisoners or immigrants. Comparator was “standard of care”, other high-risk populations or no-screening. Most of the studies are based on Markov model simulations and they mostly adopted a healthcare payer´s perspective. ICER for general population screening plus treatment versus high-risk populations or versus routinely performed screening showed to be below the accepted willingness to pay thresholds in most studies and therefore screening plus DAAs strategy is highly cost-effective.
Conclusion. This systematic review shows that screening programmes followed by DAAs treatment is cost-effective not only for high risk population but for general population too. Because today HCV can be easily cured and its long-term consequences avoided, a universal HCV screening plus DAAs therapies should be the recommended strategy to achieve the
WHO objectives for HCV eradication by 2030.

Rev Esp Quimioter 2020; 33(4): 240-248[Full-text PDF]

8 junio, 2020/por Luis Alou

Abstract, Abstract 2020

Rev Esp Quimioter 2020; 33(4): 258-266

Utility of lateral flow tests in SARS-CoV-2 infection monitorization

FRANCISCO JAVIER CANDEL GONZÁLEZ, JOSÉ MANUEL VIÑUELA-PRIETO, JUAN GONZÁLEZ DEL CASTILLO, PABLO BARREIRO GARCÍA, MARCOS FRAGIEL SAAVEDRA, ALBA HERNÁNDEZ PÍRIZ, DAVID JIMÉNEZ VIRUMBRALES, JESÚS CANORA LEBRATO, GONZALO GARCÍA DE CASASOLA, RUTH GIL PRIETO, JESÚS SAN-ROMÁN MONTERO, JUSTO ORTEGA ANSELMI, RAQUEL BARBA MARTÍN, FERNANDO PRADOS ROA, JAVIER MARCO MARTÍNEZ, ANTONIO ZAPATERO GAVIRIA

Published: 4 June 2020

http://www.doi.org/10.37201/req/052.2020

Introduction. The diagnosis of SARS-CoV-2 infection is crucial for medical and public health reasons, to allow the best treatment of cases and the best control of the pandemic. Serology testing allows for the detection of asymptomatic infections and 19-COVID cases once the virus has been cleared. We analyzed the usefulness of the SARS-CoV-2 rapid test of Autobio and tried to correlate its pattern with the severity of COVID19 infection.
Material and methods. We analyzed the accuracy and clinical usefulness of a point-of-care IgM and/or IgG test for SARS-CoV-2 in 35 COVID-19 patients [12 (34.3%) mild-moderate and 23 (65.7%) severe-critical] admitted to a field hospital in Madrid, as well as in 5 controls.
Results. The mean time from the first day of symptoms to the antibody test was 28 days (SD: 8.7), similar according to the severity of the disease. All patients with SARS-CoV-2 PCR+ showed the corresponding IgG positivity, while these results were negative in all control individuals. A total of 26 (74%) cases also presented with positive IgM, 19 (83%) were severe-critical cases and 7 (58%) were mild-moderate cases. The IgM response lasted longer in the severe critical cases (mean: 29.7 days; SD: 8.4) compared to the moderate cases (mean: 21.2 days; SD: 2.0).
Conclusions. Rapid serology tests are useful for the diagnosis of patients with COVID-19 (mainly IgG detection) and may also be correlated with the severity of the infection (based on IgM detection).

Rev Esp Quimioter 2020; 33(4): 258-266 [Full-text PDF]

4 junio, 2020/por Luis Alou